Christian Blank, Head of Melanoma and Sarcoma Division at European Institute of Oncology, shared a post on LinkedIn about an article he and his colleagues authored:
“Congrats Lotte Hoeijmakers and team with your publication ‘Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial’ in Nature Medicine, showing a melanoma specific survival of 88% and for patients achieving a MPR even 98%. Considering that PRADO used the neoadjuvant scheme endemic to NADINA these data predict the likely long-term data of NADINA.”
Title: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial
Authors: Lotte L. Hoeijmakers, Petros Dimitriadis, Steven C. M. A. Wijnen, Irene L. M. Reijers, Marta Lopez-Yurda, Alexander M. Menzies, Annegien Broeks, Sten Cornelissen, Alejandro Torres Acosta, Anja van der Wal, Robyn P. M. Saw, Judith M. Versluis, Winan J. van Houdt, Michel W. Wouters, Jurriaan Romano, Eliza A. Rozeman, Lindsay G. Grijpink-Ongering, Ellen Kapiteijn, Astrid A. M. van der Veldt, Karijn M. Suijkerbuijk, Hanna Eriksson, Geke A. P. Hospers, Jos A. van der Hage, Dirk J. Grünhagen, Arjen J. Witkamp, Judith M. Lijnsvelt, Willem C. M. Klop, Charlotte L. Zuur, Annemarie Bruining, Abrahim Al-Mamani, Thomas E. Pennington, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Maria Gonzalez, Andrew J. Spillane, John B. A. G. Haanen, Robert V. Rawson, Richard A. Scolyer, Bart A. van de Wiel, Alexander C. J. van Akkooi, Georgina V. Long, Christian U. Blank
More posts featuring Christian Blank on OncoDaily.
